The role of cGMP hydrolysing phosphodiesterases 1 and 5 in cerebral artery dilatation

Author： Kruuse C.   Rybalkin S.D.   Khurana T.S.   Jansen-Olesen I.   Olesen J.   Edvinsson L.  

Publisher： Elsevier

ISSN： 0014-2999

Source： European Journal of Pharmacology, Vol.420, Iss.1, 2001-05, pp. : 55-65

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential

By Sybertz E.   Czarniecki M.  

Expert Opinion on Therapeutic Patents, Vol. 7, Iss. 6, 1997-06 ,pp. : 631-639

Informa Healthcare

Access to resources Recommend Favorite

cGMP Signaling, Phosphodiesterases and Major Depressive Disorder

By  

Current Neuropharmacology, Vol. 9, Iss. 4, 2011-12 ,pp. : 715-727

Bentham Science Publishers

Access to resources Recommend Favorite

Influence of phosphodiesterases and cGMP on cAMP generation and on phosphorylation of phospholamban and troponin I by 5-HT4 receptor activation in porcine left atrium

By Weninger Sabine   Maeyer Joris   Lefebvre Romain  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 386, Iss. 8, 2013-08 ,pp. : 671-684

Springer Publishing Company

Access to resources Recommend Favorite

cGMP-kinase mediates cGMP- and cAMP-induced Ca 2+ desensitization of skinned rat artery

By Kawada T.   Toyosato A.   Islam M.O.   Yoshida Y.   Imai S.  

European Journal of Pharmacology, Vol. 323, Iss. 1, 1997-03 ,pp. : 75-82

Elsevier

Access to resources Recommend Favorite

Nitrergic relaxation of the horse corpus cavernosum. Role of cGMP

By Recio P.   Lopez P.G.   Hernandez M.   Prieto D.   Contreras J.   Garca-Sacristan A.  

European Journal of Pharmacology, Vol. 351, Iss. 1, 1998-06 ,pp. : 85-94

Elsevier

Access to resources Recommend Favorite